Characteristics of Patients Receiving Budesonide/Glycopyrronium/Formoterol for Chronic Obstructive Pulmonary Disease in Spain: The AURA Study
Single-inhaler BGF triple therapy was initiated mostly as an escalation from dual maintenance therapy, with many switching from triple therapy, in patients with a high burden of disease, as demonstrated by their frequent exacerbation profile, advanced COPD severity (moderate to very severe obstruction) and the high frequency of several comorbidities, including cardiovascular diseases.
Authors
- Lina Johana Herrera-Parra (ORCID: https://orcid.org/0000-0002-2582-3869)
- Joaquín Sánchez-Covisa (ORCID: https://orcid.org/0000-0002-6407-3669)
- Myriam Calle Rubio (ORCID: https://orcid.org/0000-0002-3890-2742)
- Juan Antonio Trigueros (ORCID: https://orcid.org/0000-0001-9180-2268)
- Michael Pollack (ORCID: https://orcid.org/0000-0001-7351-3059)
- Paula Chaparro Briones
- Ignacio Hernández Subira
Institutions
- Instituto de Salud Carlos III (ES)
- Madrid Health Service (ES)
- AstraZeneca (Switzerland) (CH)
- Primary Health Care (QA)
- AstraZeneca (Spain) (ES)
Publication Details
- Journal
- International Journal of COPD
- Published
- 2025-04-01
- DOI
- https://doi.org/10.2147/copd.s490227
- Citations
- 3
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 4.56
Funders
- AstraZeneca
- AstraZeneca España